NextCure, Inc.

NextCure, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing targeted cancer therapies, including antibody-drug conjugates. Its pipeline includes SIM0505 and LNCB74, and the company also maintains a dedicated manufacturing facility to support clinical development.

4.14

4.14

— NextCure, Inc.
%
Clinical-stage ADC programs70% Development of antibody-drug conjugate oncology candidates for patients with unmet need.
Licensed ADC platform technology20% Use of licensed ADC technology to develop additional proprietary antibody-based candidates.
Research and discovery platform10% Biology, biomarker, and tumor microenvironment research used to identify targets and candidates.

NextCure does not currently sell commercial products; its work is directed toward future patients with cancer,...

  • Future oncology patientsprimary

    Patients with cancers that do not respond to current therapies; they are the intended beneficiaries of approved products.

  • Clinical trial sites and investigatorsprimary

    Hospitals and physicians that enroll patients and administer study protocols for SIM0505, LNCB74, and other candidates.

  • Contract development and manufacturing organizationssecondary

    Third parties that manufacture ADC intermediates and drug product or support clinical supply.

  • Potential future healthcare providers and payorssecondary

    Oncologists, hospitals, and insurers that would influence adoption and reimbursement after approval.

  • Licensing and collaboration partnerssecondary

    Partners that may provide upfront fees, development support, or commercialization rights in selected territories.

NextCure is headquartered in the United States and conducts its core research, development, and corporate activities...

  • •Headquartered and primarily operated in the United States
  • •Clinical development and corporate functions are U.S.-based
  • •SIM0505 rights exclude China, Hong Kong, Macau, and Taiwan
  • •Third-party manufacturing may involve non-U.S. facilities
  • •Foreign regulatory and trade rules can affect CMO access

NextCure’s strategy is to advance SIM0505 and LNCB74 through clinical development and, if successful, toward regulatory...

01
Advance lead ADC programsshort-term

Clinical progress is the main value driver for a company without commercial revenue.

02
Secure additional fundingshort-term

Development programs require capital before any product revenue can be generated.

03
Preserve development optionalitymedium-term

Partnerships and licensing can broaden resources and reduce single-asset dependence.

04
Maintain manufacturing readinessmedium-term

ADC programs require reliable clinical supply and future commercial scalability.

NextCure faces the typical risks of a clinical-stage biotech company: no approved products, dependence on clinical...

critical

Clinical development failure

Pipeline value depends on proving safety and efficacy in human studies.

Scope
SIM0505, LNCB74 and future candidates
Materiality
high
critical

Financing risk

The company has no product sales and must raise capital to continue operations.

Scope
Equity dilution, debt terms, partnership dependence
Materiality
high
high

Third-party manufacturing and trial execution

CROs and CDMOs control key steps in development and supply.

Scope
Clinical timelines, product supply, data quality
Materiality
high
high

Regulatory and healthcare compliance

Drug approval, promotion, and commercial arrangements are heavily regulated.

Scope
FDA review, anti-kickback and fraud-and-abuse rules
Materiality
medium
medium

Foreign manufacturing and trade restrictions

Some manufacturing is tied to non-U.S. facilities and counterparties.

Scope
CMO access, supply continuity, geopolitical disruption
Materiality
medium
Clinical trial accruals
Can shift expense recognition between periods
Share-based compensation valuation
Affects G&A and R&D expense levels
Going-concern assessment
Important for liquidity disclosure and investor interpretation
No revenue recognition from product sales
Reported results are dominated by operating expenses and financing activity

Xencor Inc

XNCR · Pharmaceutical Preparations

OnKure Therapeutics, Inc.

OKUR · Pharmaceutical Preparations

NovoCure Ltd

NVCR · Surgical & Medical Instruments & Apparatus

Oric Pharmaceuticals, Inc.

ORIC · Pharmaceutical Preparations

Corbus Pharmaceuticals Holdings, Inc.

CRBP · Pharmaceutical Preparations

LeonaBio, Inc.

LONA · Biological Products, (No Diagnostic Substances)

: 29/04/2026